:: Volume 11, Issue 3 (10-2022) ::
Int J Med Invest 2022, 11(3): 0-0 Back to browse issues page
Systematic Review of The Molecular Diagnosis of The Endometrial Carcinoma
Shahla Abbasi *
Gynocologist,Department of Medical Education,Shahid Beheshti university of Medical Science, Tehran,Iran
Abstract:   (565 Views)

Background: Today, the diagnosis and staging of endometrial cancer are surgical and pathological procedures, but other non-invasive diagnostic methods, such as molecular diagnostic methods are being used with caution. So, this study aimed at reviewing current molecular diagnostic methods to clarify available methods for further accuracy analyses. 
Methods: This was a systematic review. PubMed and Scopus databases were queried with relevant.  All articles related to the topic were selected. Then, the search results were reviewed based on the relationship between the title of the article and then the abstract and text of the article with the aim of research. The articles found were published in the period 2008 to 2022. Only qualitative analysis was performed. 
Results:  Finally, 11 retrospective studies were found along with a meta-analysis study.  CA-125, HE4, Serum-Amyloid-A, Sperm-associated antigen 9, YKL-40, and Visfatin were individual factors assessed as diagnostic or prognostic factor along with some studies evaluating panel of proteins for prediction of the endometrial cancer. Most studies showed valuable diagnostic features of the evaluated proteins and panels versus being prognostic. 
Conclusion: Advances in molecular biology in recent decades have helped enhance researchers' to predict endometrial cancer that available choices should be more evaluated for preparation for clinical use. 
Keywords: Endometrial cancer, Endometrial carcinoma, Molecular biomarker, Visfatin, CA-125, HE4
Type of Study: Review | Subject: General

XML     Print

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 11, Issue 3 (10-2022) Back to browse issues page